Login to Your Account



Vicuron Plans NDA Filing After Dalbavancin Phase III Analysis

By Kim Coghill


Friday, August 13, 2004
Vicuron Pharmaceuticals Inc.'s stock soared 21.9 percent Thursday after the firm said it would seek regulatory approval later this year on favorable data from a Phase III program of once-weekly dalbavancin in skin and soft-tissue infections caused by Gram-positive bacteria. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription